UNASSIGNED: TPS249 Background: Imaging technologies monitoring and predicting @entity0 response to neoadjuvant chemotherapy (NAC) are of increasing interest. The utility of conventional imaging approaches varies and identifies the need for alternate functional imaging strategies. DOSI is a promising experimental technology that allows @entity1 undergoing NAC to be followed with a "no significant risk" device meeting Food and Drug Administration criteria for exempt status. The current design is a mobile device which offers increased accessibility. DOSI is relatively simple to perform and interpret, as compared to mammography, magnetic resonance imaging, and positron emission tomography. Due to its size and portability, DOSI is a low barrier-to-access technology, creating new opportunities for @entity1 to receive personalized treatment and for physicians to gain new insight into response mechanisms. Our long-term goal is to provide oncologists with a relatively simple, risk-free bedside tool that can be used to help inform medical decisions on chemotherapy regimen, duration, and timing of surgery, thereby maximizing therapeutic response and minimizing unnecessary toxicity. METHODS: In this phase I/II multicenter study, @entity1 who have been diagnosed with @entity0 , have had confirmation by pre-treatment biopsy, and are scheduled to receive NAC followed by surgery are eligible for this trial. Approximately 60 @entity1 receiving NAC will participate at five clinical sites. This protocol will evaluate a harmonized DOSI technology platform that has been standardized for NAC monitoring. The primary aim of this clinical trial is to determine whether the baseline to mid-therapy changes in the DOSI measurement of the quantitative @entity5 tissue optical index can predict final pathologic complete response in @entity1 with @entity0 undergoing NAC. The secondary aims investigate the correlation between additional DOSI quantitative measurements of @entity5 biochemical composition obtained at other timepoints, the full range of pathologic response (i.e. complete, partial, and non-response), and any corresponding imaging measurements.

ACRIN 6691 monitoring and predicting XXXX neoadjuvant chemotherapy response using diffuse optical spectroscopic imaging (DOSI).

@entity1 :: ('9606', 'Species') :: ['patients', 'women'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
